The global market for Predictive Breast Cancer diagnostic and drug
Technologies was valued at $23.4 billion in 2010 and came down to $21.2
billion in 2011. This market is expected to rise at a compound annual growth
rate (CAGR) of 2.5% and reach $24 billion by 2016.
The market for Breast cancer drugs reached $12.7 billion in 2010 and came
down to $10.2 billion in 2011. The market is expected to reach $11.2 billion
by 2016, a CAGR of 1.9%.
The Quantitative immunofluorescence market reached $5.7 billion in 2010
and reached to $5.9 billion in 2011. The market is expected to reach $6.9
billion by 2016, a CAGR of 3.1%.
SUMMARY FIGURE
GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND
DRUG TECHNOLOGIES, 2010 - 2016 ($ MILLIONS)
Source: BCC Research
STUDY GOALS AND OBJECTIVES
This BCC market research report provides a detailed overview and thorough
analysis of the present and future global market for breast cancer diagnostics
and drug technologies. It provides detailed analysis of the breast cancer drug
and diagnostics markets, as well as the currently used personalized,
predictive and companion tests and their markets. The research also includes
market characterization, opportunities, the unmet needs associated with breast
cancer, competitive assessment, product profiles of major marketed products
and promising drugs in the pipeline, an overview on discontinued projects,
implications for future market competition and the key players of the breast
cancer market.
This report includes products in this market and detailed analyses of markets
and competitive environments. It also analyzes current and future market
prospects. It provides a comprehensive review of emerging breast cancer
personalized and predictive diagnostic tests, particularly with regard to
companion tests, tumor markers and gene profiling assays relevant for breast
cancer prognosis and diagnosis. The analysis reviews technological
developments, product innovations and recent strategic industry activity of
major players across different product categories. It analyzes their strengths
and weaknesses, opportunities and threats facing various devices and drugs in
this market space and developments already on the market. It discusses the
major issues involved in the research and development (R&D) of more effective
devices for drug delivery to the lungs, along with new products in development.
REASONS FOR DOING THE STUDY
According to the National Cancer Institute, more than 200,000 women in the
U.S. are diagnosed with breast cancer annually. It is no longer necessary for
one breast cancer treatment to fit all cases, a concept that should be welcome
news for physicians and their patients alike. Personalized medicine is
relatively new to the market research report format, and it provides business
tools to evaluate new commercial opportunities in diagnostics and biomarker
fields. The scope of this report covers global companies developing tests
relevant for breast cancer prognosis and diagnosis. This study describes
current products in each area, identifies current market participants, and
most importantly, notes the trends that will affect further product
development in this area.
Companion diagnostics is also a part of the personalized medicine revolution.
The field evolved as a continuation of biomarker studies and diagnostics
testing. The breast cancer predictive testing segment of the industry is still
growing; it has a number of successful FDA - approved products. This study
will provide knowledge of the current state of the companion diagnostics
industry and the new technologies in assay development. More importantly, it
will describe potential and novel commercial developments in this area. The
report will also provide an overview covering major biotechnology and pharma
companies involved in developing innovative, targeted breast cancer treatments
that address major unmet medical needs to advance cancer care. In addition,
the report also provides information regarding the less-developed sectors of
this market and presents a list of current companies that have new predictive
testing products and drugs in development for breast cancer.
SCOPE AND FORMAT
This report will provide an update and on overview on predictive testing in
breast cancer diagnostics and drug technologies and global markets. The
study's objective is to review the tumor marker-based predictive companion
tests and drugs for breast cancer, and then assess their global growth
potential over a five-year period from 2011 to 2016. Review includes global
markets for breast cancer incidence, current drugs, new developments,
predictive diagnostic tests, market trends and new technologies, and
developments and forecast trends for the use of current tests for better
diagnosis and prognosis for breast cancer through 2016. Important tests,
technologies and developments; market share by drug, test, current products on
the market and market share by company or product; and statistical information
for types of breast cancer prevalence globally, with special emphasis on the
U.S. market, are discussed. The report focuses on tumor marker-based testing
that provides vital information about the cancer. These tests can help
determine the appropriate medicine and timing of treatment to address the
disease most effectively. The report also includes current issues and trends
affecting the industry. The report covers products in development, new
technologies, trends, alliances, patents and mergers. It offers market data
with respect to segments and geography. Other breast cancer detection and
screening technologies and markets (e.g., mammography, ultrasound, biopsy) are
not included in this report.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this
report. Secondary sources include books, newspapers, trade journals, white
papers, industry portals, government agencies, trade associations, industry
news, and paid and free databases. The base year of the report is 2010, with
forecast data provided through 2016. Historical, base year and forecast data
are provided for each market segment of this report.
The report provides a comprehensive review of breast cancer incidence,
development of the disease, drugs currently used and diagnostic technologies
based on tumor markers for accurate diagnosis and aid in deciding treatment
plans for patients. The new analysis reviews technological developments,
product innovations and introductions, and recent strategic industry activity
of major players across various product categories. Growth rates, global
incidence and projections are determined through a compilation of data,
including past trends, future trends, demographics, incidence, mortality,
products in R&D and current product growth. A comprehensive and exhaustive
search of the literature on breast cancer assay development and already -
marketed products, breast cancer global incidence and latest drug developments
was conducted. These secondary sources included scientific-related journals
and articles, textbooks, press releases, marketing literature, other product
or promotional literature, annual reports and security analyst reports. Patent
searches and analyses were also conducted. Some informal interviews were also
conducted with experts and personnel in this area at biotech and
pharmaceutical companies. Other resources included academic, technology
transfer offices and consulting companies.
ANALYST CREDENTIALS
Usha Nagavarapu is a pharmaceutical professional with experience in
scientific and alliance development. This includes more than 10 years of drug
and device product development and alliance management experience. She has
managed preclinical discovery programs from target identification through
design of Phase I testing, including IND enabling studies, and assisted
out-licensing and portfolio development activities. Strong focus areas include
oncology, dermatology and cardiovascular diseases. She has extensive
experience working with early-start-ups to fulfill operational obligations
while minimizing overall operational cost and burden.
Table of Contents
Table of Contents
Breast Cancer Diagnostic and Drug Technologies: Global Markets
Chapter - 1: INTRODUCTION - Complimentary
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE AND FORMAT
INTENDED AUDIENCE
METHODOLOGY
RELATED BCC STUDIES
ANALYST CREDENTIALS
BCC ON-LINE SERVICES
DISCLAIMER
Chapter - 2: SUMMARY
Table Summary: GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND
DRUG TECHNOLOGIES, THROUGH 2016
Figure Summary: GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND
DRUG TECHNOLOGIES, 2010 - 2016
Chapter - 3: OVERVIEW
BREAST CANCER DIAGNOSTICS AND TRENDS
BREAST CANCER
MAMMOGRAPHY
TYPES OF BREAST CANCER
THE FUTURE OF BREAST CANCER DETECTION
Chapter - 4: BIOMARKERS AND DEVELOPMENT OF CANCER DIAGNOSTICS
BIOMARKERS AND CANCER
BIOMARKERS AND BREAST CANCER
HER2
INCREASED USE OF BIOMARKERS IN DRUG DEVELOPMENT AND CLINICAL TRIALS
Chapter - 5: BREAST CANCER
SYNOPSIS
BREAST CANCER CAUSES
Table 26: SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS SUMMARY STAGE
SYSTEM FOR BREAST CANCER
Chapter - 6: BREAST CANCER PREVALENCE AND INCIDENCE RATES
CANCER INCIDENCE ACROSS THE GLOBE
FAMILY HISTORY OF BREAST CANCER AND GENETIC PREDISPOSITION
Chapter - 7: BREAST CANCER DRUGS AND MARKET TRENDS
CLINICAL DIAGNOSIS AND MANAGEMENT
TRIPLE NEGATIVE BREAST CANCER
NEW MEDICINES FOR BREAST CANCER
CONCLUSIONS
Table 59: APPROVED ONCOLOGY DRUGS, 2012
Table 60: APPROVED ONCOLOGY DRUGS, 2011
Table 61: APPROVED ONCOLOGY DRUGS, 2010
Chapter - 8: BREAST CANCER PREDICTIVE DIAGNOSTICS MARKET
CANCER COSTS PROJECTED TO REACH AT LEAST $158 BILLION IN 2020
KEY COMPANYIES
GENOMIC ASSAYS
CONCLUSIONS
Chapter - 9: COMPANY PROFILES
ABBOTT LABORATORIES
AETERNA ZENTARIS
AGENDIA
ALTHEADX
AMBERGEN INC.
ASTRAZENECA PLC
ATOSSA GENETICS INC.
BIOTIME
CCC DIAGNOSTICS LLC
CLARINET
DAKO
EISAI INC. (HEADQUARTERS)
EUTROPICS PHARMACEUTICALS
FLUXION BIOSCIENCES
GENENTECH
GENOMIC HEALTH
GLAXOSMITHKLINE
LIFE TECHNOLOGIES
MDXHEALTH
MERCK AND COMPANY INC.
MYRIAD GENETICS
NANOSTRING TECHNOLOGIES
NEKTAR
PFIZER
PHIGENIX
RUBICON GENOMICS
SANOFI US
VENTANA MEDICAL SYSTEMS INC.
Chapter - 10: DEVELOPMENTS AND COLLABORATIONS
CURRENT DEVELOPMENTS AND FUTURE
Chapter - 11: REFERENCES
List of Tables
Summary Table: GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND
DRUG TECHNOLOGIES, THROUGH 2016
Table 1: POSSIBLE SIGNS OF BREAST CANCER
Table 2: DIAGNOSTIC MAMMOGRAM FOR BREAST CANCER
Table 3: BREAST CANCER GRADES
Table 4: BIOPSY OR SURGERY SAMPLE TESTING
Table 5: TESTS USED TO EVALUATE DIFFERENT GENE SETS
Table 6: IMAGING TESTS THAT DETERMINE IF BREAST CANCER HAS SPREAD
Table 7: HER2 TESTING AND VARIATIONS
Table 8: GUIDELINES FOR EARLY DETECTION OF BREAST CANCER IN AVERAGE RISK,
ASYMPTOMATIC WOMEN
Table 9: BREAST CANCER SCREENING RECOMMENDATIONS BY THE USPSTF
Table 10: BREAST CANCER PROGNOSTIC FACTORS
Table 11: BREAST CANCER PREDICTIVE FACTORS
Table 12: RECURRENCE RATES AT FIVE YEARS IN PATIENTS WITH LYMPH NODES THAT
ARE POSITIVE FOR CANCER
Table 13: FIVE-YEAR SURVIVAL RATES CORRELATED WITH TUMOR STAGE
Table 14: PREDICTIVE DIAGNOSTIC FEATURES
Table 15: CURRENT BIOMARKER TECHNOLOGIES
Table 16: BIOMARKER USES
Table 17: MAJOR ISSUES AND CHALLENGES
Table 18: PHARMACOGENOMICS TESTS IN USE
Table 19: BIOMARKERS FOR DRUG LABELS BASED ON SPECIFIC USE
Table 20: CANCER BIOMARKERS FOR FDA-MANDATED TESTING PRIOR TO DRUG USE
Table 21: CLINICALLY RELEVANT BIOMARKERS
Table 22: APPROVED COMPANION DIAGNOSTICS, 2011
Table 23: REGULATORY APPROVAL OF THE DIAGNOSTICS PATHWAY
Table 24: APPROVED CANCER DRUGS, 2011
Table 25: FACTORS INFLUENCING THE CHOICE OF A DIAGNOSTICS PARTNER
Table 26: SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS SUMMARY STAGE SYSTEM
FOR BREAST CANCER
Table 27: MAIN TYPES OF BREAST CANCER
Table 28: BREAST CANCER EVALUATION TESTS
Table 29: TREATMENT PLAN
Table 30: HORMONE THERAPY
Table 31: CANCER STAGES
Table 32: RISK FACTORS OF RECURRENCE AFTER SUCCESSFUL TREATMENT FOR BREAST
CANCER
Table 33: BREAST CANCER PREVENTION MEASURES
Table 34: AMERICAN CANCER SOCIETY'S DIETARY GUIDELINES FOR CANCER
PREVENTION
Table 35: BREAST CANCER INCIDENCE AND MORTALITY GLOBALLY, 2008
Table 36: ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010 - 2016
Table 37: NEW BREAST CANCER CASES BY GEOGRAPHIC REGION, 2009
Table 38: EFFECTIVE EDUCATION AND SCREENING ADVANTAGES IN THE U.K. AND THE
U.S.
Table 39: CRUDE AND EUROPEAN AGE-STANDARDIZED BREAST CANCER INCIDENCE
RATES PER 100,000 POPULATIONS IN THE U.K., 2008
Table 40: U.K. ESTIMATED INCIDENCE OF BREAST CANCER, 2010-2016
Table 41: GERMAN ESTIMATED INCIDENCE OF BREAST CANCER AND PROJECTIONS,
2010-2016
Table 42: CHINESE ESTIMATED INCIDENCE OF BREAST CANCER, 2008 - 2016
Table 43: INDIA ESTIMATED INCIDENCE OF BREAST CANCER, 2008-2016
Table 44: JAPAN ESTIMATED INCIDENCE OF BREAST CANCER, 2010
Table 45: FIVE-YEAR SURVIVAL FOR BREAST CANCER
Table 46: BREAST CANCER FIVE-YEAR SURVIVAL BY CANCER STAGE
Table 47: U.S. ESTIMATED INCIDENCE OF BREAST CANCER, 2010 - 2016
Table 48: U.S. ESTIMATED NEW FEMALE BREAST CANCER CASES AND DEATHS BY AGE,
2011
Table 49: U.S. ESTIMATED INCIDENCE OF BREAST CANCER, 2012
Table 50: COMPARISON OF BREAST CANCER INCIDENCE AND DEATH IN MEN AND
WOMEN, 2012
Table 51: ESTIMATED BREAST CANCER INCIDENCE, 2004-2008, AND MORTALITY,
2003-2007
Table 52: BREAST CANCER ESTIMATES IN ASIAN WOMEN, INCIDENCE, 2004-2008,
AND MORTALITY, 2003-2007
Table 53: ESTIMATED BREAST CANCER INCIDENCE IN HISPANIC AND LATINA WOMEN,
2004 - 2008, AND MORTALITY, 2003 - 2007
Table 54: BREAST CANCER RISK WITH AGE
Table 55: U.S. RATES, TRENDS AND CAUSE-SPECIFIC SURVIVAL FOR FEMALE BREAST
CANCER PATIENTS BY RACE OR ETHNICITY, 2001-2007
Table 56: RELATIVE CANCER SURVIVAL IN WOMEN
Table 57: CANADA ESTIMATED NUMBER OF NEW BREAST CANCER CASES IN FEMALES BY
AGE, 2010
Table 58: AUSTRALIA PROJECTED NEW CASES OF BREAST CANCER, 2011-2021
Table 59: APPROVED ONCOLOGY DRUGS, 2012
Table 60: APPROVED ONCOLOGY DRUGS, 2011
Table 61: APPROVED ONCOLOGY DRUGS, 2010
Table 62: DRUGS APPROVED FOR BREAST CANCER
Table 63: HORMONE THERAPY FOR BREAST CANCER
Table 64: AROMATASE INHIBITORS FOR TREATING BREAST CANCER
Table 65: CHEMOTHERAPY DRUGS FOR TREATING BREAST CANCER
Table 66: COMMONLY USED COMBINATIONS
Table 67: MEDICINES TO CONTROL AND PREVENT NAUSEA AND VOMITING
Table 68: MARKET FOR TARGETED CANCER DRUGS, 2008 AND 2016
Table 69: TARGETED THERAPUETICS FOR BREAST CANCER
Table 70: GLOBAL PHARMACEUTICAL SALES, THROUGH 2016
Table 71: BREAST CANCER THERAPY SALES, THROUGH 2016
Table 72: BREAST CANCER DRUG MARKET, 2010 AND 2016
Table 73: AROMATASE INHIBITORS MARKET, 2010 AND 2016
Table 74: BREAST CANCER TARGETED THERAPIES, 2010 AND 2011
Table 75: ROCHE SALES COMPARED TO THE GLOBAL MARKET, 2010
Table 76: XELODA SALES, 2010 AND 2011
Table 77: ROCHE-SALES VERSUS THE GLOBAL MARKET, 2011
Table 78: EXPECTED SALES FOR PERTUZUMAB, 2016
Table 79: CANCER THERAPY SALES, 2008 AND 2018
Table 80: AUSTRALIA TARGETED CANCER THERAPY SALES, 2008 AND 2018
Table 81: ANTINEOPLASTIC MABS MARKET, 2008 AND 2014
Table 82: U.S. PERSONALIZED MEDICINE MARKET, THROUGH 2016
Table 83: U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED
THERAPIES MARKET, THROUGH 2016
Table 84: GLOBAL MOLECULAR DIAGNOSTICS MARKET, THROUGH 2016
Table 85: GLOBAL IVD MARKET, THROUGH 2016
Table 86: NEXT-GENERATION CANCER DIAGNOSTIC PRODUCTS BY TYPE, THROUGH 2016
Table 87: ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010 - 2016
Table 88: GLOBAL INCIDENCE OF ESTROGEN RECEPTOR POSITIVE BREAST CANCER
CASES, 2010 - 2016
Table 89: PREDICTIVE TECHNOLOGY
Table 90: BREAST CANCER DIAGNOSTIC TEST COSTS
Table 91: GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC
TECHNOLOGIES, THROUGH 2016
Table 92: IHC AND FISH-BASED BREAST CANCER TESTING SALES, THROUGH 2016
Table 93: FDA-APPROVED COMMERCIAL KITS
Table 94: FDA-APPROVED FISH ANALYSIS TESTS
Table 95: ROCHE SALES BY DIVISION, 2010
Table 96: ROCHE COMPANION DIAGNOSTICS CURRENTLY ON THE MARKET OR IN LATE
DEVELOPMENT FOR BREAST CANCER
Table 97: GENOMIC MARKET LEADERS
Table 98: GENOMIC TESTING MARKET FOR BREAST CANCER, THROUGH 2016
Table 99: ONCOTYPE DX SALES, THROUGH 2016
Table 100: QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST
CANCER, THROUGH 2016
Table 101: RESULTS OF A SURVEY BY MEDCO AND THE AMERICAN MEDICAL
ASSOCIATION, 2009
List of Figures
Summary Figure: GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND
DRUG TECHNOLOGIES, 2010 - 2016
Figure 1: GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2008
Figure 2: ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010 - 2016
Figure 3: U.K. ESTIMATED INCIDENCE OF BREAST CANCER, 2010 - 2016
Figure 4: GERMAN ESTIMATED INCIDENCE OF BREAST CANCER, 2010 - 2016
Figure 5: CHINESE ESTIMATED INCIDENCE OF BREAST CANCER, 2010 - 2016
Figure 6: INDIA ESTIMATED INCIDENCE OF BREAST CANCER, 2010 - 2016
Figure 7: U.S. ESTIMATED INCIDENCE OF BREAST CANCER, 2010 - 2016
Figure 8: GLOBAL PHARMACEUTICAL SALES, 2010 - 2016
Figure 9: BREAST CANCER THERAPY SALES, 2010 - 2016
Figure 10: BREAST CANCER DRUG MARKET, 2010 AND 2016
Figure 11: U.S. PERSONALIZED MEDICINE MARKET, 2010 - 2016
Figure 12: U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED
THERAPIES MARKET, 2010 - 2016
Figure 13: NEXT-GENERATION CANCER DIAGNOSTIC PRODUCTS BY TYPE, 2010 - 2016
Figure 14: GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC
TECHNOLOGIES, 2010 - 2016
Figure 15: IHC AND FISH-BASED BREAST CANCER TESTING SALES, 2010 - 2012
Figure 16: GENOMIC TESTING MARKET FOR BREAST CANCER, 2010 - 2016
Figure 17: QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST
CANCER, 2010 - 2016
Breast Cancer Diagnostic and Drug Technologies: Global Markets published by BCC Research in June 22, 2012. This report consists of 166 pages and the price starts from US $ 5450.
Press Release
Global Market for Predictive Breast Cancer Technologies to Reach $24 Billion in 2016
July 17th, 2012
Global Information Inc. would like to present a new market research report, "Breast Cancer Diagnostic and Drug Technologies: Global Markets" by BCC Research.
The market for predictive diagnostic and drug technologies concerning breast cancer was valued at $21.2 billion in 2011. This figure is projected to reach nearly $24.1 billion in 2016, a five-year compound annual growth rate (CAGR) of 2.5%.
The market for predictive breast cancer diagnostic and drug technologies can be broken down into four categories: breast cancer drugs, quantitative immunofluorescence, genomic analysis, and immunohistochemical (IHC) testing and fluorescent in situ hybridization techniques (FISH).
Breast cancer drugs accounted for $10.2 billion in 2011 and should total $11.2 billion in 2016, a CAGR of 1.9%.
Quantitative immunofluorescence totaled $5.9 billion in 2011 and should reach $6.9 billion in 2016, a CAGR of 3.1%.
Genomic analysis was worth $4.4 billion in 2011 and in 2016 should be worth nearly $5.2 billion, a CAGR of 3.1%.
IHC and FISH accounted for nearly $678 million in 2011 and are expected to be worth nearly $788 million in 2016, a CAGR of 3.1%.
Breast cancer is the most diagnosed cancer in women and is the leading cause of death among women globally. Increased public awareness and improved screening have led to earlier diagnosis, significantly improving survival rates, particularly in younger women. Unfortunately, many early breast cancer growths are not associated with pain or discomfort, and therefore are first detected as abnormalities on mammograms before patients or healthcare providers notice them. The general approach to evaluation of breast cancer involves a clinical examination, which includes imaging (usually mammography and/or ultrasonography) and needle biopsy.
It is estimated that breast cancer will affect one in eight American women during their lifetime. The World Health Organization estimates that 1.38 million new cases were diagnosed globally in 2008, up from approximately 500,000 cases in 1975. The WHO projects that more than 2.1 million new cancer cases will be diagnosed in 2030. The United States has the highest annual incidence rates of breast cancer in the world. In 2010 alone, an estimated 261,100 women in the United States were newly diagnosed with breast cancer. The affordability of treatment is often a concern for women with breast cancer diagnoses. Rising healthcare costs have left a number of patients either uninsured or with less meaningful coverage than they need and deserve.
This report is an exhaustive study on the global breast cancer market, giving crucial statistics and analyses on existing drugs, diagnostic technologies, latest trends, market structure, market size, key drug segments, important trends in technology development, major opportunities, and market shares of key players and drugs. This information may prove crucial for the firms or investors seeking opportunities in the concerned sector.
